BAM7 decreased 24 h viability in Bak−/− mouse embryo fibroblasts that retain BAX over a 3.75–15 μM treatment series. BAX-deficient cells were resistant, and wild-type BAX reconstitution restored sensitivity while the K21E mutant did not. These genetic comparisons support BAX dependence in the tested MEF context. [1]
BAM7 responses also depended on cellular context. In TERT-immortalized HUVECs, 20 μM BAM7 decreased the viability signal and increased apoptosis in mock cells, whereas RasGRP2-overexpressing cells were protected. The study therefore supports BAM7 as a probe of BAX-associated apoptosis while showing that a protective signaling background can limit its cellular effect. [2]
BAX binding and trigger-site mapping
Biochemical assay · Recombinant full-length human BAX; FITC–BIM SAHB competition and 15N-BAX NMR [1]
BAM7 displaced FITC–BIM SAHB from BAX. Resynthesized BAM7 retained comparable competition potency. NMR perturbations were concentrated near the α1/α6 trigger-site region; the docked pose is a structural model, not a solved ligand-bound structure.
Literature-Reported Treatment Conditions
- Treatment concentration
- Serial BAM7 dilution; competition assay used 50 nM FITC–BIM SAHB and 500 nM BAX. NMR titration up to a 1:1 BAX:BAM7 ratio.
- Exposure duration
- Competition fluorescence polarization read at 20 min.
- Method
- Competitive fluorescence polarization and 1H–15N HSQC NMR
- Reported limits
- Assay vehicle not recovered from the cited binding methods; no KD is assigned from competition IC50.
Methods and source locations
Compound reported in the paper: BAM7; Compound label in the paper: BAM7 (compound 1)
Research findings for the reported BAM7 material and model; no salt conversion or commercial-lot potency certification.
Figure 1c,d; Figure 2a–c; Results/Discovery and Structural analysis; Methods/BAM7 characterization; SI/Fluorescence polarization binding assays and NMR samples
Displacement of FITC–BIM SAHB from BAX: Competitive fluorescence polarization; Figure 1c printed fit annotation — Figure 1c (printed annotation) and caption
Displacement by resynthesized BAM7: Competitive fluorescence polarization; mean and s.d. for experiments performed in at least triplicate — Figure 1c (printed annotation) and caption
BAX chemical-shift mapping: 15N-BAX titration; calculated chemical-shift significance threshold >0.009 p.p.m.; no affinity value extracted — Figure 2a and caption; Results/Structural analysis
BAX-dependent liposomal membrane permeabilization
Biochemical assay · Purified BAX or BAX K21E with ANTS/DPX-loaded liposomes [1]
BAM7 promoted BAX-dependent membrane permeabilization. BAM7 alone, BAX alone, BAX K21E with BAM7, and BAX with inactive analog ANA-BAM16 did not induce release in this assay. This is an isolated membrane system, not an animal experiment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 400 nM BAX; Figure 3b BAX:BAM7 ratios 1:1, 1:2, 1:4, 1:6, 1:8, 1:10 and 1:20.
- Exposure duration
- 90 min endpoint; assay monitored at 30 °C.
- Method
- ANTS/DPX dequenching normalized to maximal release induced by tBID plus BAX.
- Reported limits
- Assay vehicle not specified in the targeted SI liposomal-release method. No absolute release percentages inferred from bars.
Methods and source locations
Compound reported in the paper: BAM7; Compound label in the paper: BAM7 (compound 1)
Research findings for the reported BAM7 material and model; no salt conversion or commercial-lot potency certification.
Figure 3b and caption; Results/Functional activation; SI/Liposomal release assay
Liposomal content release: ANTS/DPX liposomal release; Figure 3 caption reports mean and s.d. for experiments performed in at least triplicate. BIM SAHB positive comparator at BAX:peptide 1:2. — Figure 3b and caption; SI/Liposomal release assay
Genetic controls for BAM7-associated loss of MEF viability
Cell-based study · Bak−/−, Bax−/− and Bax−/−Bak−/− mouse embryo fibroblasts; double-knockout MEFs reconstituted with wild-type BAX or BAX K21E [1]
BAM7 reduced viability in Bak−/− MEFs that retain BAX, while Bax−/− and double-knockout cells were resistant under the tested conditions. Wild-type BAX reconstitution restored sensitivity, whereas K21E reconstitution did not. ANA-BAM16 lacked the BAM7-specific pattern.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 3.75, 5.00, 7.50, 10.00 and 15.00 μM BAM7; matched ANA-BAM16 dose series.
- Exposure duration
- 24 h
- Method
- CellTiter-Glo luminescent viability assay, normalized to vehicle-treated controls.
- Vehicle
- 0.15% (v/v) DMSO
- Reported limits
- No cellular IC50 adopted; results are restricted to these engineered MEF models.
Methods and source locations
Compound reported in the paper: BAM7; Compound label in the paper: BAM7 (compound 1)
Research findings for the reported BAM7 material and model; no salt conversion or commercial-lot potency certification.
Figure 3c–e and caption; Results/cellular BAX dependence; Methods/Cell viability assay
Cell viability across BAX/BAK genotypes and BAX reconstitution: CellTiter-Glo at 24 h; mean and s.d. for experiments performed in at least triplicate. ANA-BAM16 comparator. — Figure 3c–e and caption; Methods/Cell viability assay
RasGRP2 expression limits the endothelial response to BAM7
Cell-based study · TERT-immortalized HUVECs: mock (M) versus RasGRP2-stable-overexpression (R) cells [2]
At 20 μM, BAM7 reduced the viability signal and increased NucView-positive apoptosis in mock cells, but not in RasGRP2-overexpressing cells. Values are relative to the 0 h viability signal, not to each time-matched untreated control.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20 μM BAM7
- Exposure duration
- 24 h and 48 h for viability; 24 h for NucView apoptosis.
- Method
- Cell Counting Kit-8 viability assay and NucView 488 apoptosis imaging.
- Reported limits
- Vehicle is not specified in the retrieved Methods. Figure caption n=3 is retained; Methods describe duplicate experiments repeated at least two or three times without defining independent biological n for each plotted point.
Methods and source locations
Compound reported in the paper: BAM7; Compound label in the paper: BAM7
Research findings for the reported BAM7 material and model; no salt conversion or commercial-lot potency certification.
Figure 1a,c,d; Results/RasGRP2 inhibits apoptosis; Methods/Reagents, Cell cultures, Cell viability, Measurement of apoptosis, Statistical analysis
Mock-cell viability at 24 h; 0 h = 100%: Cell Counting Kit-8; exact numbers from Results, not the curve — Results first paragraph; Figure 1a and caption
Mock-cell viability at 48 h; 0 h = 100%: Cell Counting Kit-8 — Results first paragraph; Figure 1a and caption
RasGRP2-overexpressing-cell viability at 24 h; 0 h = 100%: Cell Counting Kit-8; no significant reduction reported — Results first paragraph; Figure 1a and caption
RasGRP2-overexpressing-cell viability at 48 h; 0 h = 100%: Cell Counting Kit-8; no significant reduction reported — Results first paragraph; Figure 1a and caption
NucView-positive apoptosis at 24 h: NucView 488 detects caspase-3 activation; ratio normalized to mock-cell control; mean ± SD (n=3). No exact bar heights extracted. — Figure 1c,d and caption; Results second paragraph; Methods/Measurement of apoptosis